Engineered t cells take on Hard-to-Treat KRAS cancers
NCT ID NCT05389514
First seen Nov 20, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tests a new treatment for people with advanced cancers that have a specific genetic change called KRAS G12V. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. Participants must also have a specific immune system type (HLA-DRB1*07:01). The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.